Chronic Myelogenous Leukemia, Version 1.2015

• DOI: 10.6004/jnccn.2014.0159
• Publication Date: 2017-04-14T16:04:33Z
• Authors: Susan O’Brien; Jerald P. Radich; Camille N. Abboud; Mojtaba Akhtari; Jessica K. Altman; Ellin Berman; Peter Curtin; Daniel J. DeAngelo; Michael Deininger; Steven Devine; Amir T. Fathi; Jason Gotlib; Madan Jagasia; Patricia Kropf; Joseph O. Moore; Arnel Pallera; Vishnu VB. Reddy; Neil P. Shah; B. Douglas Smith; David S. Snyder; Meir Wetzler; Kristina Gregory; Hema Sundar
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Leukemia, Myeloid, Chronic-Phase; Hematopoietic Stem Cell Transplantation; Humans; Antineoplastic Agents; Guidelines as Topic; Leukemia, Myeloid, Accelerated Phase; Protein-Tyrosine Kinases; Protein Kinase Inhibitors; 3. Good health

Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.